Arbovirus Testing Market 2025 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

Arbovirus testing market

The global market value of the arbovirus testing market was estimated to be 1.1 billion in 2023 and is projected to grow at a CAGR of 7.1% during the forecast period. Rising healthcare expenditure and increasing awareness of government-neglected tropical diseases such as dengue and chikungunya caused by arbovirus are driving the demand in the market.

The pharmaceutical and biotech sectors are intensifying research and development efforts. The focus on creating targeted therapies, vaccines, and novel diagnostic methods—such as next-generation sequencing and multiplex assays—addresses unmet needs and opens new market opportunities, particularly in regions heavily affected by these diseases.

Rising awareness among the people about these diseases is the key cause behind the significant growth in the market. Increasing numbers of cases of Zika and West Nile virus are driving demand for diagnostics, treatments, and vaccines. Global warming, deforestation, and urban expansion are creating favorable conditions for vector breeding.

The rise of invasive mosquito species like Aedes albopictus increases disease transmission risks. Development of AI-driven and biosensor-based diagnostic tools enhances accuracy.

Growth Drivers

Rising awareness about the public health campaigns and investments in mosquito control measures are rising. Travel-related risks are pushing demand for pre-travel vaccinations and protective measures. Ongoing efforts to develop broad-spectrum antivirals for flaviviruses and alphaviruses are driving demand in the market significantly.

Urbanization also plays a significant role, as densely populated cities with poor sanitation provide ideal breeding grounds for these vectors. Additionally, globalization and increased international travel facilitate the spread of these viruses across borders, introducing them to new regions and populations.

Biotech firms exploring monoclonal antibodies and RNA-based therapies for emerging arbovirus threats are expanding growth in the market significantly. Vector control strategies like genetically modified mosquitoes and Wolbachia bacteria are gaining traction. Global warming, deforestation, and urban expansion are creating favorable conditions for vector breeding.

 One major driver is the rising incidence of arboviral infections, such as dengue, Zika, chikungunya, and West Nile virus. This increase is fueled by factors like climate change, which expands the habitats of vectors like mosquitoes by creating warmer and more humid conditions conducive to their proliferation.

Segmentation

Infectious Diseases IVD Product

·         Instruments

§  MRSA

§  Streptococcus

§  Clostridium Difficile

§  VRE

§  CRE

§  Respiratory Virus

§  Candida

§  TB and Drug-resistant TB

§  Gastro-intestinal Panel Testing

§  Chlamydia

§  Gonorrhea

§  HPV

§  HIV

§  Hepatitis C

§  Hepatitis B

§  COVID-19

§  Others Infectious Diseases

o   Reagents

§  MRSA

§  Streptococcus

§  Clostridium Difficile

§  VRE

§  CRE

§  Respiratory Virus

§  Candida

§  TB and Drug-resistant TB

§  Gastro-intestinal Panel Testing

§  Chlamydia

§  Gonorrhea

§  HPV

§  HIV

§  Hepatitis C

§  Hepatitis B

§  COVID-19

§  Others Infectious Diseases

o   Software Services

§  MRSA

§  Streptococcus

§  Clostridium Difficile

§  VRE

§  CRE

§  Respiratory Virus

§  Candida

§  TB and Drug-resistant TB

§  Gastro-intestinal Panel Testing

§  Chlamydia

§  Gonorrhea

§  HPV

§  HIV

§  Hepatitis C

§  Hepatitis B

§  COVID-19

§  Others Infectious Diseases

Infectious Diseases IVD Technology

·         Immunoassay

·         Molecular Diagnostics

o   Polymerase Chain Reaction (PCR)

o   In Situ Hybridization

o   Isothermal Nucleic Acid Amplification Technology (INAAT)

o   Chips and Microarrays

o   Sequencing & NGS

o   Transcription Mediated Amplification

·         Others

·         Microbiology

Infectious Diseases IVD Application

·         MRSA

·         Streptococcus

·         Clostridium Difficile

·         VRE

·         CRE

·         Respiratory Virus

·         Candida

·         TB and Drug-resistant TB

·         Gastro-intestinal Panel Testing

·         Chlamydia

·         Gonorrhea

·         HPV

·         HIV

·         Hepatitis C

·         Hepatitis B

·         COVID-19

·         Others Infectious Diseases

Infectious Diseases IVD Test Location

·         Point of Care

·         Central Laboratories

·         Others

By Region

·         Asia-Pacific

·         North America

·         Latin America

·         Middle East and Africa

·         Europe

Arbovirus testing market on the basis of application

On the basis of the application, the arbovirus testing market is segmented into MRSA, Streptococcus Clostridium Difficile, VRE, CRE, Respiratory Virus, Candida, TB and Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19, and Other Infectious Diseases.

Respiratory virus testing is the leading segment in the market, and is expected to dominate during the forecast period. During pandemic the number of patients suffering from novel corona virus has increased drastically, and HIV, HPV, and hepatitis (B & C) testing also holds substantial market share due to their high global disease burden, and routine screening requirements. Rising healthcare expenditure in all over the world is driving growth in the market significantly.

Regional Outlook

On the basis of the regions, The Arbovirus testing market is segmented into 5 regions: Asia-Pacific, North America, Latin America, Middle East and Africa, and Europe. North America is the leading region due to rapidly growing population, and a significant burden of diseases such as West Nile virus.

 North America is getting benefit from well-established healthcare infrastructure that facilitates the adoption of advanced diagnostic technologies. There is a considerable funding directed towards the development of innovative diagnostic tools for arbovirus detection.

The Asia-Pacific region is expected to witness significant growth during the forecast period because Asia-Pacific is home to some of the world’s most densely populated countries, such as India, China, and Indonesia.

Rapid urbanization in these areas often outpaces infrastructure development, leading to poor sanitation, inadequate waste management, and stagnant water accumulation—perfect conditions for vector proliferation. With large populations at risk, especially in urban slums and rural areas, the demand for diagnostic tools surges to enable early detection and containment.

Government initiatives and healthcare investments also play a pivotal role. Countries like India, China, and Australia have prioritized arbovirus surveillance and control programs, often in collaboration with international bodies like the WHO. For example, India’s National Vector Borne Disease Control Program focuses heavily on diseases like dengue, increasing the adoption of diagnostic tests. Public health campaigns and funding for affordable, rapid testing solutions—like point-of-care kits—cater to both urban hospitals and remote areas, expanding market reach.

Key Players

·         Agilent Technologies, Inc.

·         Thermo Fisher Scientific.

·         NovaTec Immundiagnostica GmbH.

·         Euroimmun AG.

·         Abbott Laboratories

·         DiaSorin S.p.A.

·         Hologic Inc.

·         Siemens Healthcare GmbH

·         Inverness Medical Innovations

·         Chembio Diagnostics

·         Ortho Clinical Diagnostics

·         Abbott Laboratories

·         Alere Inc.

·         HoffmannLa Roche Ltd

·         Trinity Biotech Plc

·         Thermo Fisher Scientific Inc.

·         QIAGEN N.V.

·         BioRad Laboratories

·         Danaher Corporation

·         Other Players